Irinotecan for Advanced and Metastatic Breast Cancer

Liaoning Cancer Hospital & Institute124 enrolled

Overview

This trial aims to evaluate the safety and efficacy of third-line or later irinotecan treatment for locally recurrent or metastatic breast cancer among Chinese patients who have received at least two regimens containing anthracyclines and taxanes.

Anthracyclines and taxanes are the most effective first-line and second-line treatments for breast cancer, although increased usage in early treatment lines can make it difficult to select a third-line or later treatment. This issue is further complicated by the fact that patients with metastatic breast cancer can become resistant to anthracyclines and taxanes. Thus, there are no consistent international guidelines regarding treatment in this setting. In China, the treatment procedures for metastatic breast cancer follow the National Comprehensive Cancer Network guidelines, which recommend single-drug treatments for recurrent or metastatic disease, which typically involve anthracyclines, taxanes, vinorelbine, gemcitabine, capecitabine, and eribulin. However, there is no standard international recommendation for patients with metastatic breast cancer who have developed resistance to anthracyclines and taxanes, and there are limited options for third-line or later treatment in this setting. This trial aims to evaluate the safety and efficacy of third-line or later irinotecan treatment for locally recurrent or metastatic breast cancer among Chinese patients who have received at least two regimens containing anthracyclines and taxanes.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

124

Conditions

Breast Cancer

Interventions

IrinotecanDRUG

The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age of 18-70 years; * Female patients with histologically or cytologically confirmed breast cancer; * Patients with locally recurrent or metastatic breast cancer who have been treated with at least two chemotherapy regimens; * Measurable lesions (based on computed tomography or magnetic resonance imaging) that have a longest diameter of ≥ 10 mm based on the RECIST v1.1 criteria and a shortest lymph node diameter of ≥ 15 mm; * Eastern Cooperative Oncology Group (ECOG) grade 0-2; * Life expectancy of ≥ 12 weeks; * Adequate bone marrow capacity, hepatic functional reserve, and renal functional reserve within 7 days before screening: Absolute neutrophils count: 1.5 × 109/L Hemoglobin: ≥ 9.0 g/dL; * Platelet count: ≥ 80 × 109/L Total bilirubin: \< 1.5 times the ULN Aspartate and alanine transaminases: ≤ 2.5 times the ULN (≤ 5 times the ULN for liver metastases) Alkaline phosphatase:\< 4 times the ULN Serum creatinine: ≤ 1.5 times the ULN * Women of childbearing age requiring effective contraception; * Provision of informed consent. Exclusion Criteria: * Receiving chemotherapy, radiotherapy, HER2/neu-targeted drugs (including trastuzumab), or hormonal therapy within 3 weeks; * Breast cancer patients who do not receive local treatment and develop brain and dural metastasis. However, patients will be eligible if corticosteroids for brain and dural metastasis have been withdrawn for at least 4 weeks, if the signs and/or symptoms of brain metastasis have been stable for ≥ 4 weeks, and if imaging findings confirm that the disease is stable between the screening and 4 weeks earlier; * Severe cardiovascular injury (congestive heart failure of class II or worse based on the New York Heart Association classification), unstable angina, myocardial infarction, or severe arrhythmia during the past 6 months; * A history of human immunodeficiency virus infection, chronic hepatitis B, or hepatitis C (high viral DNA copyl DNA ti) at the active phase; * Clinical evidence of other severe active infection; * Patients with homozygous mutations in UGT1A1\*6 and/or UGT1A1\*28 (these patients are susceptible to irinotecan-induced diarrhea); * Patients with allogeneic organ transplants that require immunosuppressive therapy; * A history of other malignancies within 5 years, except for cured cervical carcinoma in situ or basal cell skin cancer. Women who are pregnant, lactating, or within their childbearing age but not using adequate contraception; * Drug abuse and medical, psychological, or social conditions that could interfere with the patient's ability to consent or that might affect the study's results; * Known or suspected being allergy to the studied drug or any other drug administered in the study; * Any unstable condition that might jeopardize the patient's safety and compliance.

Locations (1)

Cancer Hospital of China Medical University

Shenyang, Liaoning, China

Outcomes

Primary Outcomes

Objective response rate (ORR)

The ORR will be calculated based on the number of patients who achieve a complete or partial response divided by the total sample size.

Time frame: 1 year

Secondary Outcomes

Progression-free survival(PFS)

The PFS interval will be calculated from the start of irinotecan treatment to the first instance of tumor progression, treatment failure, or death from any cause. Overall survival will be calculated from the start of irinotecan treatment to death from any cause.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.